NASDAQ: PROKProkidney Corp Stock
$2.71+0.00 (+0%)
Updated Apr 25, 2024
PROK Price
$2.71
Fair Value Price
$0.91
Market Cap
$621.52M
52 Week Low
$1.12
52 Week High
$13.51
P/E
-4.75x
P/B
-0.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.03
Operating Cash Flow
-$90M
Beta
0.59
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PROK Overview
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PROK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PROK ($2.71) is overvalued by 197.4% relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PROK ($2.71) is not significantly undervalued (197.4%) relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PROK due diligence checks available for Premium users.
Be the first to know about important PROK news, forecast changes, insider trades & much more!
PROK News
Valuation
PROK fair value
Fair Value of PROK stock based on Discounted Cash Flow (DCF)
Price
$2.71
Fair Value
$0.91
Overvalued by
197.40%
PROK ($2.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PROK ($2.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PROK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.75x
Industry
15.41x
Market
40.97x
PROK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.56x
Industry
5.8x
PROK's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
PROK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$420.6M
Liabilities
$29.2M
Debt to equity
-0.03
PROK's short-term assets ($374.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PROK's short-term assets ($374.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PROK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PROK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.4M
Investing
-$95.8M
Financing
-$9.5M
PROK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PROK vs Biotech Stocks
Prokidney Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.